TO THE Director OF Pharmaceutical Import Profile — Sudan (DGFT 2022–2026)

Name: TO THE Director OF Pharmaceutical Import Records from India — 3 Products, $4.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO THE Director OF — Pharmaceutical Importer Profile (2026) | 3 Products, $4.1M Trade | TransData Nexus

TO THE Director OF

Pharmaceutical Importer · Sudan · Advanced Antibiotics Focus · $4.1M Total Trade · DGFT Verified

TO THE Director OF is a pharmaceutical importer based in Sudan with a total trade value of $4.1M across 3 products in 1 therapeutic categories. Based on 175 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. TO THE Director OF sources from 5 verified Indian suppliers, with Scott Edil Pharmacia Limited accounting for 59.6% of imports.

TO THE Director OF — Import Portfolio & Supplier Network

TO THE Director OF import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO THE Director OF?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Scott Edil Pharmacia Limited	$9.7M	1,003	59.6%
Scott-edil Advance Research Laboratories & Educati	$6.0M	266	36.8%
B.m.pharmaceuticals	$341.6K

What Formulations Does TO THE Director OF Import?

Formulation	Value	Ships
Harmless pharmaceutical medicines finished formulation ceftriaxone for INJ USP 1000MG packed into 10ML clear glass	$410.9K	16
Harmless pharmaceutical medicines finished formulation ceftriaxone for injectionusp 1000MG packed in 10ML clear glass	$317.3K	18
Harmless pharmaceutical medicines finished formulation ampicillin trihydrate 250MG BP & cloxacillin sodium 250MG BP cap.	$158.2K	5
Harmless pharmaceutical medicines finished formulation cefuroxime for INJ USP 750MG futum 750MG INJ plst wfi batch no.	$150.0K	3
Pharmaceutical products formulations erythropoietin injection BP 4000iu/ML b.no:xv4e015 m-05/2024 e	$109.9K	4
Harmless pharmaceutical medicines finished formulation cefixime cap 200 MG b.no.4754z001 to 4754z003 mfg.01/2024	$107.5K	3
Harmless pharmaceutical medicines finished formulation ceftriaxone for INJ USP 1000MG packed in 10ML clear glass	$102.9K	3
Harmless pharmaceutical medicines finished formulation ampicillin trihydrate 250MG BP & cloxacillin sodium 250MG BP CAPS	$100.0K	2
"harmless pharmaceutical medicines finished formulation amoxycillin & clavulanate potassium tablets USP	$100.0K	2
Harmless pharmaceutical medicines finished formulation cefixime 400MG capsulesb.no:0704z017 mfg-12/24	$100.0K	2
Harmless pharmaceutical medicines finished formulation cefixime capsules USP 400MG b.no: 0704z018 & 0704z019 mfg-12/24	$100.0K	2
Harmless pharmaceutical medicines finished formulation amoxicillin & clavulanatepotassium tablets USP 625MG	$100.0K	2
Harmless pharma medicines finished formquinine di hydrochloride BP injection 500MG 2ML a2512727 to	$100.0K	2
Pha. med. fin. pro. for. ceftriaxone forinj USP 1000MG packed in 10 ML clear glass vials with	$95.3K	2
Harmless pharmaceutical medicines finished formulation cefuroxime axetil tabletsusp 500 MG b.no.0734z002 mfg.01/2024	$93.6K	3

TO THE Director OF imports 812 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ceftriaxone	Advanced Antibiotics	$2.3M	97	0.8%	9
2	Cefixime	Advanced Antibiotics	$1.7M	75	1.0%	12
3	Ceftazidime	Advanced Antibiotics	$100.5K	3	0.9%	12

TO THE Director OF imports 3 pharmaceutical products across 1 categories into Sudan totaling $4.1M.

TO THE Director OF — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO THE Director OF is a pharmaceutical importer and buyer based in Sudan, specializing in the procurement of finished pharmaceutical formulations from India. The company has established itself as a significant player in Sudan's pharmaceutical supply chain, focusing on advanced antibiotics. With a total import value of $4.1 million USD over 175 shipments, TO THE Director OF demonstrates a robust engagement in the importation of critical medical supplies. The company's portfolio is highly concentrated, with its top three products—Ceftriaxone, Cefixime, and Ceftazidime—accounting for 100% of its imports. This strategic focus underscores TO THE Director OF's commitment to providing essential antibiotics to meet the healthcare needs of the Sudanese population.

2Distribution Network

While specific details about TO THE Director OF's warehouse locations and logistics capabilities are not publicly available, the company's substantial import volume suggests a well-established distribution network within Sudan. The efficient handling of 175 shipments indicates a capacity to manage complex logistics operations, ensuring timely delivery of pharmaceutical products across the country. Given the critical nature of the imported antibiotics, it is likely that TO THE Director OF collaborates with local distributors and healthcare facilities to ensure widespread availability of its products.

3Industry Role

TO THE Director OF plays a pivotal role in Sudan's pharmaceutical supply chain as a primary importer of essential antibiotics. By focusing exclusively on advanced antibiotics, the company addresses a critical segment of the market, ensuring the availability of these life-saving medications. Its significant import volume and product concentration position TO THE Director OF as a key supplier to hospitals, clinics, and pharmacies throughout Sudan, contributing to the overall healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO THE Director OF

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The sourcing strategy of TO THE Director OF reveals a high degree of supplier concentration, with five verified Indian suppliers accounting for the entirety of its imports. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or geopolitical issues affecting trade relations. However, the consistent import volumes from these suppliers over multiple years suggest a stable and reliable relationship, mitigating potential risks associated with such concentration. The company's focus on a limited number of suppliers may also allow for more favorable terms and streamlined logistics.

2Supply Chain Resilience

TO THE Director OF's supply chain resilience appears robust, given the consistent importation of a diverse range of 812 unique pharmaceutical formulations from its five Indian suppliers. This diversity in formulations indicates a strategic approach to sourcing, reducing dependency on any single product line and enhancing the company's ability to adapt to changing market demands. While the concentration of suppliers could be a vulnerability, the established relationships and diversified product range suggest a well-prepared supply chain capable of maintaining stability in the face of potential disruptions.

Strategic Implications

Importing Pharmaceuticals into Sudan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sudan

1Regulatory Authority & Framework

In Sudan, the National Medicines and Poisons Board (NMPB) serves as the primary regulatory authority overseeing the importation, manufacturing, and distribution of pharmaceutical products. Established under the Drugs and Toxins Act of 2009, the NMPB is responsible for ensuring the safety, efficacy, and quality of medicines available in the country. The NMPB's mandate includes the registration of pharmaceutical products, inspection of manufacturing facilities, and enforcement of regulations to prevent the circulation of counterfeit or substandard medicines. The NMPB collaborates with international organizations, such as the World Health Organization (WHO), to align Sudan's pharmaceutical regulations with global standards. (emro.who.int)

2Import Licensing & GMP

Importers in Sudan must obtain a license from the NMPB to legally import pharmaceutical products. This process involves submitting an application that includes detailed information about the products, their manufacturers, and compliance with Good Manufacturing Practice (GMP) standards. The NMPB requires that foreign manufacturers provide a Certificate of Pharmaceutical Product (CPP) issued by the health authority in the exporting country, authenticated by the Sudanese Ministry of Foreign Affairs. This certificate must detail the product's composition and confirm that it is registered and freely sold in the country of origin. Additionally, the NMPB conducts inspections of manufacturing facilities to ensure adherence to GMP guidelines, with overseas manufacturers typically inspected every five years. (nmpb.gov.sd)

TO THE Director OF — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO THE Director OF's exclusive focus on advanced antibiotics—Ceftriaxone, Cefixime, and Ceftazidime—aligns with the critical healthcare needs in Sudan, where antibiotic resistance and infectious diseases are prevalent concerns. The substantial import values of these products indicate a strong market demand and a strategic decision to concentrate on high-impact therapeutic areas. By specializing in these antibiotics, TO THE Director OF positions itself as a key supplier of essential medications, contributing significantly to the treatment of bacterial infections in the country.

2Sourcing Profile

TO THE Director OF's sourcing strategy is centered on importing finished pharmaceutical formulations from India, a country known for its robust pharmaceutical manufacturing sector. The company's focus on advanced antibiotics suggests a preference for high-quality, effective treatments that meet international standards. India's adherence to WHO-GMP guidelines and its established reputation in the global pharmaceutical market make it a reliable source for these critical medications. This sourcing approach ensures that TO THE Director OF can provide Sudanese healthcare providers with essential antibiotics that are both effective and accessible.

3Market Positioning

Seller's Guide — How to Become a Supplier to TO THE Director OF

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Sudanese market by partnering with TO THE Director OF. The company's established distribution network and focus on advanced antibiotics present a platform for introducing additional products that meet the therapeutic needs of the Sudanese population. Potential gaps in TO THE Director OF's current sourcing, such as the inclusion of other essential antibiotics or related therapeutic categories, could be addressed by new suppliers, thereby expanding the product portfolio and enhancing market presence.

2Requirements & Qualifications

Indian exporters seeking to supply TO THE Director OF and the Sudanese market must ensure that their products are registered with the NMPB and comply with Sudanese regulations. This includes providing a Certificate of Pharmaceutical Product (CPP) issued by the health authority in the exporting country, authenticated by the Sudanese Ministry of Foreign Affairs. Additionally, manufacturers must adhere to Good Manufacturing Practice (GMP) standards, with inspections conducted by the NMPB to verify compliance. Labeling must be in English, detailing the product's composition, dosage, and usage instructions. (nmpb.gov.sd)

How to Approach

Frequently Asked Questions — TO THE Director OF

What products does TO THE Director OF import from India?

TO THE Director OF imports 3 pharmaceutical products across 1 categories. Top imports: Ceftriaxone ($2.3M), Cefixime ($1.7M), Ceftazidime ($100.5K).

Who supplies pharmaceuticals to TO THE Director OF from India?

TO THE Director OF sources from 5 verified Indian suppliers. The primary supplier is Scott Edil Pharmacia Limited (59.6% of imports, $9.7M).

What is TO THE Director OF's total pharmaceutical import value?

TO THE Director OF's total pharmaceutical import value from India is $4.1M, based on 175 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO THE Director OF focus on?

TO THE Director OF imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full TO THE Director OF Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.